INSM

Insmed
D

INSM

97.760
USD
-0.48
(-0.48%)
مغلق
حجم التداول
36,516
الربح لكل سهم
-5
العائد الربحي
-
P/E
-16
حجم السوق
18,569,651,112
أصول ذات صلة
A
ALKS
-0.200
(-0.69%)
28.790 USD
AMGN
AMGN
1.79
(0.60%)
298.52 USD
A
ARWR
-0.120
(-0.71%)
16.790 USD
BIIB
BIIB
-1.170
(-0.88%)
132.000 USD
C
CRBP
-0.15750
(-2.03%)
7.60000 USD
GILD
GILD
-0.760
(-0.68%)
110.760 USD
L
LGND
0.950
(0.84%)
114.240 USD
REGN
REGN
-0.69
(-0.13%)
546.88 USD
VRTX
VRTX
2.24
(0.49%)
459.27 USD
المزيد
الأخبار المقالات

العنوان: Insmed

القطاع: Healthcare
الصناعة: Biotechnology
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatmentof Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterialhypertension.